Brain, Vol. 122, No. 2, 183-190,
February 1999
© 1999 Oxford University Press
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis
1 Neurology Department, MRC Cyclotron Unit, 2 Department of Immunological Medicine, Royal Postgraduate Medical School, Hammersmith Hospital and 3 Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
Correspondence to:
Dr Matthew Brett, MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK
We report a middle-aged woman with a novel transthyretin (TTR) variant, Leu12Pro. She had extensive amyloid deposition in the leptomeninges and liver as well as the involvement of the heart and peripheral nervous system which characterizes familial amyloid polyneuropathy caused by variant TTR. Clinical features attributed to her leptomeningeal amyloid included radiculopathy, central hypoventilation, recurrent subarachnoid haemorrhage, depression, seizures and periods of decreased consciousness. MRI showed a marked enhancement throughout her meninges and ependyma, and TTR amyloid deposition was confirmed by meningeal biopsy. The simultaneous presence of extensive visceral amyloid and clinically significant deposits affecting both the peripheral and central nervous system extends the spectrum of amyloid-related disease associated with TTR mutations. The unusual association of severe peripheral neuropathy with symptoms of leptomeningeal amyloid indicates that leptomeningeal amyloidosis should be considered part of the syndrome of TTR-related familial amyloid polyneuropathy.
familial amyloid polyneuropathy; oculoleptomeningeal amyloidosis; transthyretin
TTR = transthyretin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Giorgetti, S. Raimondi, S. Cassinelli, M. Bucciantini, M. Stefani, G. Gregorini, G. Albonico, R. Moratti, G. Montagna, M. Stoppini, et al. {beta}2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1176 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamashita, Y. Ando, M. Ueda, M. Nakamura, S. Okamoto, M. E. Zeledon, T. Hirahara, T. Hirai, A. Ueda, Y. Misumi, et al. Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy Neurology, January 8, 2008; 70(2): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T M O'Hearn, A Fawzi, S He, N A Rao, and J I Lim Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF Br J Ophthalmol, December 1, 2007; 91(12): 1607 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Douglass, K Suvarna, M M Reilly, P N Hawkins, and M Hadjivassiliou A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 193 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamura, T. Yamashita, M. Ueda, K. Obayashi, T. Sato, T. Ikeda, Y. Washimi, T. Hirai, Y. Kuwahara, M. T. Yamamoto, et al. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis Neurology, October 11, 2005; 65(7): 1051 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hirai, Y. Ando, M. Yamura, M. Kitajima, Y. Hayashida, Y. Korogi, T. Yamashita, and Y. Yamashita Transthyretin-Related Familial Amyloid Polyneuropathy: Evaluation of CSF Enhancement on Serial T1-Weighted and Fluid-Attenuated Inversion Recovery Images following Intravenous Contrast Administration AJNR Am. J. Neuroradiol., September 1, 2005; 26(8): 2043 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Jin, S Sato, T Takahashi, H Nakazaki, Y Date, M Nakazato, T Tominaga, Y Itoyama, and S Ikeda Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis J. Neurol. Neurosurg. Psychiatry, October 1, 2004; 75(10): 1463 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chiba, Y. Hagihara, T. Higurashi, K. Hasegawa, H. Naiki, and Y. Goto Amyloid Fibril Formation in the Context of Full-length Protein: EFFECTS OF PROLINE MUTATIONS ON THE AMYLOID FIBRIL FORMATION OF {beta}2-MICROGLOBULIN J. Biol. Chem., November 21, 2003; 278(47): 47016 - 47024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Blevins, R. Macaulay, S. Harder, D. Fladeland, T. Yamashita, M. Yazaki, K. Hamidi Asl, M. D. Benson, and J. R. Donat Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His Neurology, May 27, 2003; 60(10): 1625 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ellie, F. Camou, A. Vital, C. Rummens, G. Grateau, M. Delpech, and S. Valleix Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu) Neurology, July 10, 2001; 57(1): 135 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hund, R. P. Linke, F. Willig, and A. Grau Transthyretin-associated neuropathic amyloidosis: Pathogenesis and treatment Neurology, February 27, 2001; 56(4): 431 - 435. [Abstract] [Full Text] [PDF]
|
|